About Us
The Institute is committed to cutting edge clinical R&D in allergic inflammation and inflammatory diseases. Prosecuting and protecting intellectual property, and bring the drug leads and anti-inflammatory vaccines to pharma-licensing, and from clinical trials to the consumer market sector.
Our Founder
The Founder, Dr. Swey-Shen Alex Chen, a Harvard Ph.D. having two decades teaching and research experience in CWRU and UNMC, conceived a 501 (c) 3 organization for FDA drug discovery to deliver cutting edge biologics to the socio-economically underprivileged.
Our Team
The Institute is endowed with ten Project Lead Scientists supported by the US government NIH grants, private foundation grants and through donation. The Scientists are Ph.D. and MD from Harvard, University of Cambridge, Northwestern, Peking Union Medical College, IIT-Mumbai, Cornell University, UCSD, with decades of professional experience and expertise and peer-reviewed high impact publications.
What We Do
Affordability/Accessibility-- ability to produce cheap medicine
This 501 (c) 3 Institute excels in drug discovery while the operation runs at a significantly lower Indirect cost along with volunteers in infrastructural maintenance. Most financial effort goes into direct R&D and reagents, supplies and animal purchase and per diems.
We carry in pharma-licensing terms and stipulations that dosages and packages for children and adolescents, free or at deep discounted price delivered to the Institute according to the negotiated licensing deal. The Institute will work with community hospitals, physician and nurses, social service agents, DEA agents, and activists to identify and deliver drug products to inner city asthmatic children and adolescents.
Technology Resources
Overview
There are six modern rounds of Nobel prizes to sixteen awardees, including one round identifying the cause of IgE-mediated allergic anaphylaxis. Based on this total knowledge base, the Institute brings about the changes of innovative biologics for treated immune-mediated inflammatory diseases. The R&D within the Institute aims at discovery platforms for highly innovative, safe and efficacious biologics treating the root cause and natural history of allergic inflammation.
Platforms of drug discovery and pipelines in the Institute
The research and development programs at Institute of Genetics aims at developing biologics that downregulating allergic inflammation in the following protein and peptide discovery platform. The pipeline drugs delivered to the market will fill the draught of innovation.
1. The proprietary three dimensional in vitro protein display or ribosome/mRNA/aptamer-antibody platform aiming at reconstructing minimal broadly neutralizing IgE, allergen, HIV B-cell vaccines
2. The proprietary platform for super-beta stand-constrained, cysteine knots, and CDR3 cannonical sequences constrained B cell vaccines for treating allergic inflammation, autoimmune diseases
3. The .221 B cells/transgenic classical HLA-A,_B based octameric to decameric natural cytotoxic and immunoregulatory peptides for treating allergic inflammation, autoimmune diseases
4. Proprietary platform for discovering non-classical HLA-E based natural peptides for allergic and autoimmune diseases
5. Galectin-3 interference treating innate and adaptive immunity governing Th2, Th17 inflammation and fibrosis
6. Desensitization of peanut allergens, house dust mites, cockroach allergens through Nrf-2 transcription factor, HO-1, IL-35 -based DNA immunization